GHENT, BELGIUM--(Marketwire - February 28, 2008) - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today its results for 2007. These are the Company’s first set of results since its successful IPO and listing on Euronext Brussels in November 2007.
